Human Caucasian lung, large cell carcinoma

The cell line COR-L23/CPR is a drug-resistant variant of COR-L23 (Sigma Catalogue number. 92031919). The line was developed by growing the parent line in increasing concentrations of cisplatin. Cisplatin accumulation is reduced in COR-L23/CPR and cross resistance to melphalan and other platinum compounds has been found. Cells tend to grow in clumps.

Analysis of acquired drug resistance, study of large cell carcinoma of the lung

STR-PCR Data: Amelogenin: X
CSF1PO: 11
D13S317: 10,11
D16S539: 11,13
D5S818: 10,12
D7S820: 9
THO1: 9
TPOX: 8
vWA: 19

RPMI 1640 + 2mM Glutamine + 0.05μg / ml Cisplatin + 10% Foetal Bovine Serum (FBS).

Split sub-confluent cultures (70-80%) 1:2 to 1:5 i.e. seeding at 2-5 x 10,000 cells / cm² using 0.25 % trypsin or trypsin/EDTA; 5% CO₂; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.